Patient recruitment technology provider Massive Bio and healthcare technology provider CureMatch have partnered to advance cancer treatment through advanced genomics, AI, and clinical trial accessibility. Through the partnership, the companies will collaborate to provide oncologists and their patients with access to personalized treatments, relevant clinical trials, and reports indicating the most effective therapies based on individual patient profiles.

Additionally, through this partnership, CureMatch will utilize its platform to identify patients who might benefit from certain clinical trials, enhancing Massive Bio’s trial’s impact and reach. At the same time, Massive Bio will utilize its AI-driven platform to process patient clinical trial data for CureMatch’s customized reports, streamlining patient identification to support drug development initiatives and personalized treatment strategies.

CureMatch is a healthcare technology provider that offers oncologists with predictive treatment analytics and decision support through its online platform. Through the platform, oncologists upload patient molecular profiles, which are run through CureMatch’s database via proprietary algorithms. The algorithm analyzes the patient’s genetic information and generates a report that ranks treatments with the highest efficacy for treating that specific patient. The company’s solution has been used by healthcare providers, such as Mercy & Memorial Hospitals, and has several published case studies attesting to the platform’s efficacy.